Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
about
An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growthPerspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogsAstemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapyThe effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance.
P2860
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@ast
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@en
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@nl
type
label
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@ast
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@en
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@nl
prefLabel
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@ast
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@en
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@nl
P2093
P1433
P1476
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
@en
P2093
P304
P356
10.1016/S0090-4295(01)01254-7
P407
P433
P577
2001-08-01T00:00:00Z